MedElevator
Войти в исследования Neurologia · 2020
Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology's Headache Study Group.
СтатьяКлинические рекомендацииНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Morollón N, Belvís R, De Dios A, Pagès N, González-Oria C, Latorre G, Santos-Lasaosa S
Аннотация
INTRODUCTION: In recent months, doubts have arisen among patients, general practitioners, and neurologists as to whether some drugs commonly used in patients with headaches and neuralgia may favour or complicate the disease caused by SARS-CoV-2.
MATERIAL AND METHODS: We collected information on the opinions of scientific societies and medicines agencies (American, European, and Spanish) to clarify doubts regarding the use of drugs such as lisinopril, candesartan, ibuprofen, corticosteroids, carbamazepine, and monoclonal antibodies targeting the calcitonin gene-related peptide in the context of the COVID-19 pandemic.
RESULTS: We make recommendations about the use of standard headache treatments in the context of the COVID-19 pandemic, based on the current scientific evidence.
CONCLUSIONS: At present, there is no robust scientific argument to formally contraindicate any of the standard treatments employed for headaches and neuralgias.
MATERIAL AND METHODS: We collected information on the opinions of scientific societies and medicines agencies (American, European, and Spanish) to clarify doubts regarding the use of drugs such as lisinopril, candesartan, ibuprofen, corticosteroids, carbamazepine, and monoclonal antibodies targeting the calcitonin gene-related peptide in the context of the COVID-19 pandemic.
RESULTS: We make recommendations about the use of standard headache treatments in the context of the COVID-19 pandemic, based on the current scientific evidence.
CONCLUSIONS: At present, there is no robust scientific argument to formally contraindicate any of the standard treatments employed for headaches and neuralgias.
Предметные рубрики MeSH
Adrenal Cortex HormonesAnalgesicsAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAnticonvulsantsAntihypertensive AgentsAntiviral AgentsBenzimidazolesBetacoronavirusBiphenyl CompoundsCOVID-19Calcitonin Gene-Related Peptide Receptor AntagonistsCarbamazepineCoronavirus InfectionsDisease SusceptibilityDrug InteractionsEnzyme InductionHeadacheHumansIbuprofenLisinoprilNeuralgiaPandemicsPeptidyl-Dipeptidase APneumonia, ViralReceptors, VirusRisk FactorsSARS-CoV-2TetrazolesCOVID-19 Drug Treatment